Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia von Shanmuganathan, Naranie, Pagani, Ilaria S., Ross, David M., Park, Sahee, Yong, Agnes S.M., Braley, Jodi A., Altamura, Haley K., Hiwase, Devendra K., Yeung, David T., Kim, Dong-Wook, Branford, Susan, Hughes, Timothy P.

Volltext

Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline von Branford, Susan, Yeung, David T., Parker, Wendy T., Roberts, Nicola D., Purins, Leanne, Braley, Jodi A., Altamura, Haley K., Yeoman, Alexandra L., Georgievski, Jasmina, Jamison, Bronte A., Phillis, Stuart, Donaldson, Zoe, Leong, Mary, Fletcher, Linda, Seymour, John F., Grigg, Andrew P., Ross, David M., Hughes, Timothy P.

Volltext

Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission von Shanmuganathan, Naranie, Braley, Jodi A., Yong, Agnes S.M., Hiwase, Devendra K., Yeung, David T., Ross, David M., Hughes, Timothy P., Branford, Susan

Volltext

Nanopore sequencing with GraphMap for comprehensive pathogen detection in potato field soil von Braley, Lauren E, Jewell, Jeremy B, Figueroa, Jose, Humann, Jodi, Main, Dorrie, Mora-Romero, Guadalupe Arlene, Moroz, Natalia, Woodhall, James Warwick, White Iii, Richard Allen, Tanaka, Kiwamu

Volltext

BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia von Pagani, Ilaria S, Dang, Phuong, Kommers, Ivar O, Goyne, Jarrad M, Nicola, Mario, Saunders, Verity A, Braley, Jody, White, Deborah L, Yeung, David T, Branford, Susan, Hughes, Timothy P, Ross, David M

Volltext

Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission von Pagani, Ilaria S., Dang, Phuong, Saunders, Verity A., Grose, Randall, Shanmuganathan, Naranie, Kok, Chung H., Carne, Lisa, Rwodzi, Zandy, Watts, Sophie, McLean, Jennifer, Braley, Jodi, Altamura, Haley, Yeung, David T., Branford, Susan, Yong, Agnes S. M., White, Deborah L., Hughes, Timothy P., Ross, David M.

Volltext

Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention von Shanmuganathan, Naranie, Wadham, Carol, Shahrin, NurHezrin, Feng, Jinghua, Thomson, Daniel, Wang, Paul, Saunders, Verity, Kok, Chung Hoow, King, Rob M, Kenyon, Rosalie R, Lin, Ming, Pagani, Ilaria S, Ross, David M, Yong, Agnes S M, Grigg, Andrew P, Mills, Anthony K, Schwarer, Anthony P, Braley, Jodi, Altamura, Haley, Yeung, David T, Scott, Hamish S, Schreiber, Andreas W, Hughes, Timothy P, Branford, Susan

Volltext

Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease von Branford, Susan, Wang, Paul, Yeung, David T., Thomson, Daniel, Purins, Adrian, Wadham, Carol, Shahrin, Nur Hezrin, Marum, Justine E., Nataren, Nathalie, Parker, Wendy T., Geoghegan, Joel, Feng, Jinghua, Shanmuganathan, Naranie, Mueller, Martin C., Dietz, Christian, Stangl, Doris, Donaldson, Zoe, Altamura, Haley, Georgievski, Jasmina, Braley, Jodi, Brown, Anna, Hahn, Christopher, Walker, Ieuan, Kim, Soo-Hyun, Choi, Soo-Young, Park, Sa-Hee, Kim, Dong-Wook, White, Deborah L., Yong, Agnes S.M., Ross, David M., Scott, Hamish S., Schreiber, Andreas W., Hughes, Timothy P.

Volltext

Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells von Ross, David M., Pagani, Ilaria S., Shanmuganathan, Naranie, Kok, Chung H., Seymour, John F., Mills, Anthony K., Filshie, Robin J., Arthur, Christopher K., Dang, Phuong, Saunders, Verity A., Braley, Jodi, Yong, Agnes S., Yeung, David T., White, Deborah L., Grigg, Andrew P., Schwarer, Anthony P., Branford, Susan, Hughes, Timothy P.

Volltext

TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets von Yeung, David T., Osborn, Michael P., White, Deborah L., Branford, Susan, Braley, Jodi, Herschtal, Alan, Kornhauser, Michael, Issa, Samar, Hiwase, Devendra K., Hertzberg, Mark, Schwarer, Anthony P., Filshie, Robin, Arthur, Christopher K., Kwan, Yiu Lam, Trotman, Judith, Forsyth, Cecily J., Taper, John, Ross, David M., Beresford, Jennifer, Tam, Constantine, Mills, Anthony K., Grigg, Andrew P., Hughes, Timothy P.

Volltext

For Patients with Sustained MR4-MR4.5, Less Frequent Molecular Monitoring during the First 12 Months after Tyrosine Kinase Inhibitor Cessation Is Viable for Timely Detection of Los... von Shanmuganathan, Naranie, Branford, Susan, Braley, Jodi, Hiwase, Devendra, Yeung, David T., Ross, David M., Hughes, Timothy P.

Volltext

Achieving the Deep Molecular Response Levels Required for an Imatinib Discontinuation Trial Is Strongly Associated with the BCR-ABL Level at the First Qualifying Timepoint von Branford, Susan, Ross, David M, Yeung, David T, Braley, Jodi, Hughes, Timothy P.

Volltext

The Adverse Effect of High Sokal Risk for First Line Imatinib Treated Patients Is Overcome By a Rapid Rate of BCR-ABL Decline Measured As Early As 1 Month of Treatment von Branford, Susan, Yeung, David T, Ross, David M, Parker, Wendy T, Braley, Jodi, Seymour, John F, Hughes, Timothy P.

Volltext

Autoimmune manifestations in aged mice arise from early-life immune dysregulation von Karnell, Jodi, Mahmoud, Tamer I., Wang, Jingya, Wang, Qiming, Wang, Shu, Naiman, Brian, Gross, Philip, Brohawn, Philip Z., Morehouse, Christopher, Aoyama, Jordan, Wasserfall, Clive, Carter, Laura L, Atkinson, Mark A., Serreze, David V, Braley-Mullen, Helen, Mustelin, Tomas Mikael, Kolbeck, Roland, Herbst, Ronald, Ettinger, Rachel

Volltext